Evidence map›Paper›PMID 36139591›Full record

ArticleCancers2022

On-Clamp vs. Off-Clamp Robot-Assisted Partial Nephrectomy for cT2 Renal Tumors: Retrospective Propensity-Score-Matched Multicenter Outcome Analysis.

Aldo Brassetti, Giovanni E Cacciamani, Andrea Mari, Juan D Garisto, Riccardo Bertolo, Chandru P Sundaram, Ithaar Derweesh, Ahmet Bindayi, Prokar Dasgupta, James Porter and 22 more

Abstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

Aldo BrassettiDepartment of Urology, IRCCS "Regina Elena" National Cancer Institute, 00144 Rome, Italy.ORCID 0000-0001-9643-8979
Giovanni E CacciamaniUSC Institute of Urology and Catherine, Joseph Aresty Department of Urology, Keck School of Medicine, Los Angeles, CA 90033, USA.
Andrea MariDepartment of Experimental and Clinical Medicine, Oncologic Minimally Invasive Urology and Andrology Unit, Careggi Hospital, University of Florence, 50134 Florence, Italy.ORCID 0000-0001-9070-5706
Juan D GaristoDepartment of Urology, Cleveland Clinic, Cleveland, OH 44195, USA.
Riccardo BertoloDivision of Urology, San Carlo di Nancy Hospital, 00165 Rome, Italy.ORCID 0000-0003-0260-4601
Chandru P SundaramDepartment of Urology, Indiana University, Indianapolis, IN 47405, USA.
Ithaar DerweeshDepartment of Urology, UCSD Health System, La Jolla, CA 92103, USA.
Ahmet BindayiDepartment of Urology, UCSD Health System, La Jolla, CA 92103, USA.
Prokar DasguptaMRC Centre for Transplantation, Guy's Hospital, King's College, London WC2R 2LS, UK.
James PorterSwedish Urology Group, Seattle, WA 98104, USA.
Alexander MottrieDepartment of Urology, OLV Hospital, 9300 Aalst, Belgium.
Luigi SchipsDepartment of Urology, Annunziata Hospital, G. D'Annunzio University, 66100 Chieti, Italy.
Koon Ho RahUrological Science Institute, Yonsei University College of Medicine, Seoul 03722, Korea.
David Y T ChenDivision of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
Chao ZhangDepartment of Urology, Changhai Hospital, Shanghai 200433, China.ORCID 0000-0001-7096-8488
Kenneth JacobsohnDepartment of Urology, Medical College Wisconsin, Milwaukee, WA 53226, USA.
Umberto AnceschiDepartment of Urology, IRCCS "Regina Elena" National Cancer Institute, 00144 Rome, Italy.
Alfredo M BoveDepartment of Urology, IRCCS "Regina Elena" National Cancer Institute, 00144 Rome, Italy.
Manuela CostantiniDepartment of Urology, IRCCS "Regina Elena" National Cancer Institute, 00144 Rome, Italy.
Mariaconsiglia FerrieroDepartment of Urology, IRCCS "Regina Elena" National Cancer Institute, 00144 Rome, Italy.
Riccardo MastroianniDepartment of Urology, IRCCS "Regina Elena" National Cancer Institute, 00144 Rome, Italy.
Leonardo MisuracaDepartment of Urology, IRCCS "Regina Elena" National Cancer Institute, 00144 Rome, Italy.
Gabriele TudertiDepartment of Urology, IRCCS "Regina Elena" National Cancer Institute, 00144 Rome, Italy.
Alexander KutikovDivision of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
Wesley M WhiteDepartment of Urology, University of Tennessee Medical Center, Knoxville, TN 37920, USA.
Stephen T RyanDepartment of Urology, UCSD Health System, La Jolla, CA 92103, USA.
Francesco PorpigliaDivision of Urology, San Luigi Gonzaga Hospital, University of Turin, 10124 Orbassano, Italy.
Jihad KaoukDepartment of Urology, Cleveland Clinic, Cleveland, OH 44195, USA.
Andrea MinerviniDepartment of Experimental and Clinical Medicine, Oncologic Minimally Invasive Urology and Andrology Unit, Careggi Hospital, University of Florence, 50134 Florence, Italy.
Inderbir GillUSC Institute of Urology and Catherine, Joseph Aresty Department of Urology, Keck School of Medicine, Los Angeles, CA 90033, USA.
Riccardo AutorinoDivision of Urology, Department of Surgery, Virginia Commonwealth University Health System, Richmond, VA 23298, USA.
Giuseppe SimoneDepartment of Urology, IRCCS "Regina Elena" National Cancer Institute, 00144 Rome, Italy.ORCID 0000-0002-4868-9025

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We compared perioperative outcomes after on-clamp versus off-clamp robot-assisted partial nephrectomy (RAPN) for >7 cm renal masses. A multicenter dataset was queried for patients who had undergone RAPN for a cT2cN0cM0 kidney tumor from July 2007 to February 2022. The Trifecta achievement (negative surgical margins, no severe complications, and ≤ 30% postoperative estimated glomerular filtration rate (eGFR) reduction) was considered a surrogate of surgical quality. Overall, 316 cases were included in the analysis, and 58% achieved the Trifecta. A propensity-score-matched analysis generated two cohorts of 89 patients homogeneous for age, ASA score, preoperative eGFR, and RENAL score (all p > 0.21). Compared to the on-clamp approach, OT was significantly shorter in the off-clamp group (80 vs. 190 min; p < 0.001), the incidence of sRFD was lower (22% vs. 40%; p = 0.01), and the Trifecta rate higher (66% vs. 46%; p = 0.01). In a crude analysis, >20 min of hilar clamping was associated with a significantly higher risk of sRFD (OR: 2.30; 95%CI: 1.13−4.64; p = 0.02) and with reduced probabilities of achieving the Trifecta (OR: 0.46; 95%CI: 0.27−0.79; p = 0.004). Purely off-clamp RAPN seems to be a safe and viable option to treat cT2 renal masses and may outperform the on-clamp approach regarding perioperative surgical outcomes.

Indexed as

clinical T2hilar clampingoff-clampon-clampoutcomespartial nephrectomyrenal massrenal neoplasmrobot-assisted

Identifiers

PMID36139591
PMCPMC9496892

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.